Status:
UNKNOWN
Carbapenem-resistant Pseudomonas Aeruginosa: the SAMPAN Study.
Lead Sponsor:
Erasmus Medical Center
Collaborating Sponsors:
Dr Cipto Mangunkusumo General Hospital
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions:
Pseudomonas Aeruginosa
Colonization, Asymptomatic
Eligibility:
All Genders
18+ years
Brief Summary
Pseudomonas aeruginosa causes severe infections in hospitalized patients. The worldwide emergence of carbapenem-resistant P. aeruginosa (CR-PA) makes infections by these pathogens almost untreatable. ...
Eligibility Criteria
Inclusion
- Inclusion Criteria healthy individuals:
- All healthy individuals living in a "high-risk area" in Rotterdam, Rome or Jakarta.
- Exclusion Criteria healthy individuals:
- No signed consent sheet
- Inclusion Criteria patients:
- Must be aged 18 years or older;
- Should be capable of providing answers to the questions in the questionnaire by himself/herself;
- Should have a minimum expected length of stay of at least 24 hours;
- Inclusion only once during the sampling year.
- Exclusion Criteria patients:
- Cystic fibrosis patients
- No signed consent sheet.
Exclusion
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT05282082
Start Date
March 1 2022
End Date
March 1 2024
Last Update
April 1 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr Cipto Mangunkusumo General Hospital
Jakarta, Indonesia
2
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
3
Erasmus Medical Center
Rotterdam, South Holland, Netherlands, 3015 GD